Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer
2019 ◽
Vol 108
◽
pp. 120-128
◽
Keyword(s):
Phase 2
◽